Good evening :)
$
₹
Pacific Biosciences of California

Pacific Biosciences of California

PACB

NASDAQ
Asset Logo

Pacific Biosciences of California

PACB

NASDAQ
$2.285.92% (-0.14)
$
₹
$2.285.92% (-0.14)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Small Cap

With a market cap of $792.6M the stock is ranked 2946

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

170.66
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.43
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

-0.17
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-82.49%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 8 analysts reports

Buy
4 analysts
Hold
3 analysts
Sell
1 analyst

Price Upside

+4.65%

Earnings Growth

+0.4%

Rev. Growth

-0.81%

See Detailed Forecast

Company Profile

Company Profile

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
37.24
37.24
1Y Return
19.25%
19.25%
Buy Reco %
85.18
85.18
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
34.60
34.60
1Y Return
20.71%
20.71%
Buy Reco %
68.18
68.18
Waters Corporation
WAT
Waters Corporation
P/E Ratio
195.64
195.64
1Y Return
21.8%
21.8%
Buy Reco %
78.26
78.26
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
P/E Ratio
32.18
32.18
1Y Return
25.54%
25.54%
Buy Reco %
90.00
90.00
Illumina Inc
ILMN
Illumina Inc
P/E Ratio
38.99
38.99
1Y Return
85.02%
85.02%
Buy Reco %
47.61
47.61
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 4.65% growth, versus a trailing 3-year CAGR of -29.04%.

2026
Current$2.43Baseline
Analyst Target - 1 year
Target$2.54+4.65%

All values in $

202220232024202520262027$3.93$6.22$8.51Target+4.65%
2026
Current$2.43Baseline
Analyst Target - 1 year
Target$2.54+4.65%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -0.81% growth, versus a trailing 3-year CAGR of 7.64%.

2025
Current$160.00Baseline
Forecast for Dec 2026
High$161.96+1.23%
Average$158.71-0.81%
Low$153.3-4.19%

All values in $ Million

202120222023202420252026130.51128.30200.52154.01160.00Low-4.19%Average-0.81%High+1.23%
2025
Current$160.00Baseline
Forecast for Dec 2026
High$161.96+1.23%
Average$158.71-0.81%
Low$153.3-4.19%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.52Baseline
Forecast for Dec 2026
High$-0.5+3.85%
Average$-0.52+0.4%
Low$-0.53-1.92%

All values in $

202120222023202420252026-1.19-1.4-1.11-0.83-0.52Low-1.92%Average+0.4%High+3.85%
2025
Current$-0.52Baseline
Forecast for Dec 2026
High$-0.5+3.85%
Average$-0.52+0.4%
Low$-0.53-1.92%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

44.6
-40.3
37.1
-8.2
39
-44.7
40.5
-37.8
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue36.0139.9639.2237.1539.7638.4444.6437.173940.56
Net Income-173.31-60.722.37-426.07-41.93-38-40.37-8.27-44.74-37.84
Net Profit Margin-481.26%-151.93%6.04%-1146.81%-105.44%-98.85%-90.42%-22.25%-114.69%-93.29%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Pacific Biosciences of California -170.66-0.17
Thermo Fisher Scientific Inc37.244.722.02
Agilent Technologies Inc34.606.711.48
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare PACB with any stock or ETF
Compare PACB with any stock or ETF
Comparing from
PACB
TMO
A
Loading...

Frequently asked questions

  1. Pacific Biosciences of California (PACB) share price today is $2.28 as of November 6, 2026 at 11:23 PM IST. The stock touched a day high of $2.53 and a day low of $2.24.

  2. Pacific Biosciences of California stock trades on NASDAQ under the ticker symbol PACB.

  3. Pacific Biosciences of California's market capitalization is $792.61M as of November 6, 2026 at 11:23 PM IST.

  4. Pacific Biosciences of California's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Pacific Biosciences of California's price-to-book (P/B) ratio is 170.66 as of November 6, 2026.

  6. Yes, You can buy Pacific Biosciences of California shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Pacific Biosciences of California shares in three steps: 1. Search Pacific Biosciences of California on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Pacific Biosciences of California trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Pacific Biosciences of California (PACB) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 4.3744 shares at the current price of $2.28.

Loading...